TNF Pharmaceuticals Plunges 12% on Disappointing Q2 Earnings

TNF Pharmaceuticals' stock price plummeted by 12% in pre-market trading on August 22, 2025, sparking concerns among investors about the company's recent performance and future prospects.

TNF Pharmaceuticals recently reported its fiscal 2025 Q2 earnings, revealing mixed results. While the company managed to maintain stable revenue, its earnings per share (EPS) showed a significant decline, falling short of analysts' expectations. This disappointing performance has raised questions about the company's financial health and its ability to sustain growth in the competitive biotechnology sector.

The company's EPS for the quarter was reported at $1,281.00, which was a substantial miss compared to the consensus forecast of -$2,304.00. This negative surprise has contributed to the recent sell-off in the stock, as investors reassess their positions in light of the company's underwhelming financial performance.

Looking ahead, TNF Pharmaceuticals is scheduled to announce its next earnings report in November 2025. Investors will be closely monitoring the company's performance in the coming quarters to gauge its ability to turn around its financial fortunes and regain investor confidence. The upcoming earnings announcement will be crucial in determining the stock's future trajectory and whether it can recover from its recent decline.